Literature DB >> 29059101

PREVALENCE OF POLYPOIDAL CHOROIDAL VASCULOPATHY IN WHITE PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Systematic Review and Meta-Analysis.

Thomas D Lorentzen1,2, Yousif Subhi1,2, Torben L Sørensen1,2.   

Abstract

PURPOSE: Polypoidal choroidal vasculopathy (PCV) is a disease with significant inter-ethnical differences. In this study, we systematically review the literature on the prevalence of PCV in whites referred with a diagnosis of exudative age-related macular degeneration (AMD).
METHODS: We searched PubMed, Embase, the Cochrane Library, and the Web of Science on 24 March, 2017 for studies evaluating the prevalence of PCV in white patients with exudative AMD. Data extraction and risk of bias assessments were performed in duplicate. Studies were included for a qualitative review and a meta-analysis, including subgroup analysis for differences in age and sex.
RESULTS: We included data from 11 studies (>2,200 participants). For diagnosis, indocyanine green angiography was used together with a set of supporting criteria on fundus examination and optical coherence tomography. Extramacular location was more prevalent in eyes with PCV. Drusen was present in the fellow eye in 17% to 27%. Pooled prevalence of PCV in white patients with exudative AMD was 8.7% (confidence interval 95%: 7.2%-10.3%). Patients with PCV were 3.7 years (confidence interval 95%: 2.1 years-5.3 years) younger than those with other exudative AMD. Sex did not differ significantly.
CONCLUSION: Polypoidal choroidal vasculopathy is not a rare subtype of exudative AMD in whites-it is present in approximately one in 11 patients.

Entities:  

Mesh:

Year:  2018        PMID: 29059101     DOI: 10.1097/IAE.0000000000001872

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  23 in total

Review 1.  Idiopathic polypoidal choroidal vasculopathy: a review of literature with clinical update on current management practices.

Authors:  Yamini Sahu; Niharika Chaudhary; Mukesh Joshi; Aastha Gandhi
Journal:  Int Ophthalmol       Date:  2020-10-20       Impact factor: 2.031

2.  Characteristic appearances of fundus autofluorescence in treatment-naive and active polypoidal choroidal vasculopathy: a retrospective study of 170 patients.

Authors:  Xinyu Zhao; Song Xia; Youxin Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-04-14       Impact factor: 3.117

3.  Association of CD11b+ Monocytes and Anti-Vascular Endothelial Growth Factor Injections in Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.

Authors:  Yousif Subhi; Marie Krogh Nielsen; Christopher Rue Molbech; Mads Krüger Falk; Amardeep Singh; Thomas Vauvert Faurschou Hviid; Mogens Holst Nissen; Torben Lykke Sørensen
Journal:  JAMA Ophthalmol       Date:  2019-05-01       Impact factor: 7.389

4.  Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort.

Authors:  Siyin Liu; Ramandeep Chhabra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-09       Impact factor: 3.535

5.  Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy.

Authors:  Eleftherios I Agorogiannis; Ian A Pearce; Sohraab Yadav; David G Parry; Nicholas A V Beare
Journal:  Eye (Lond)       Date:  2018-07-12       Impact factor: 3.775

Review 6.  The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration.

Authors:  Kelvin Yi Chong Teo; Mark Gillies; Samantha Fraser-Bell
Journal:  Int J Mol Sci       Date:  2018-09-03       Impact factor: 5.923

7.  Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial.

Authors:  Praveen J Patel; Hari Jayaram; Maria Eleftheriadou; Clara Vazquez-Alfageme; Niaz Islam; Gary S Rubin; Bishwanath Pal; Peter K Addison; Robin Hamilton; Simona Degli Esposti
Journal:  Ophthalmol Ther       Date:  2020-06-18

8.  Combined therapy and antivascular endothelial growth factor monotherapies for polypoidal choroidal vasculopathy: A protocol for the systematic review and network meta-analysis of efficacy and safety.

Authors:  Yun Zhang; Xun Li; Xiaoye Chen; Zhaolun Cai; Zirong Zhang; You Tang; Tiancong Chang; Misha Chen; Meixia Zhang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.889

9.  Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.

Authors:  Yuichiro Ogura; Glenn J Jaffe; Chui Ming Gemmy Cheung; Gregg T Kokame; Tomohiro Iida; Kanji Takahashi; Won Ki Lee; Andrew A Chang; Jordi Monés; Divya D'Souza; Georges Weissgerber; Kinfemichael Gedif; Adrian Koh
Journal:  Br J Ophthalmol       Date:  2021-07-22       Impact factor: 5.908

10.  T-cell differentiation and CD56+ levels in polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.

Authors:  Yousif Subhi; Marie Krogh Nielsen; Christopher Rue Molbech; Akio Oishi; Amardeep Singh; Mogens Holst Nissen; Torben Lykke Sørensen
Journal:  Aging (Albany NY)       Date:  2017-11-20       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.